Abstract
Integrase strand transfer inhibitors (INSTIs) are a preferred antiretroviral (ARV) class for the prevention of perinatal HIV during pregnancy due to their ability to suppress HIV viral load rapidly and their high barrier to drug resistance. Our primary objective was to determine if pregnant women with HIV on ARV regimens containing INSTIs were more likely to have an undetectable HIV RNA viral load at delivery. Our secondary outcome was to determine if maternal INSTIs use increased the risk of preterm birth or low birth weight infants.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
